CClinicalTrials.gg
CompletedNCT01317784BSARTAUpdated Jul 29, 2015

Behavioral Science Aspects of Rapid Test Acceptance

An interventional study of Rapid tests for HIV, HCV, HBV, and syphilis and HIV/HCV in HIV, Hepatitis C and Hepatitis B, sponsored by California State University, Long Beach. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-29.

Sponsored by California State University, Long Beach · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The relevance of this research to public health is to make it possible to test for hepatitis C and syphilis at point of care so that people will receive their results immediately instead of requiring people to wait for at least a week to get their test results. This research will make rapid tests for HIV available that can detect HIV infection earlier and are more accurate than current tests available in the United States.

Read the detailed description

This application addresses "Studies to improve access and utilization of HIV counseling and testing" for "HIV/AIDS and AIDS-related co-infections" such as "hepatitis C virus (HCV), other sexually transmitted infections (STIs)" that are part of PA-07-307 Drug Abuse Aspects of HIV/AIDS. The only rapid tests that are approved for use in the US currently are for HIV infection. Tests for other conditions such as hepatitis C (HCV) and syphilis are in use in other countries. In response to an Opportunity that the CDC published in the Federal Register, there are now candidate rapid test kits for HCV and syphilis available for experimental use in the US. Different combinations of rapid and standard tests will be offered to participants in a four-arm trial to assess which tests are accepted by the participants. Only a minority of clients at CBRS who have been offered the rapid test for HIV have accepted it. Those who chose rapid HIV tests were more likely to be male, educated, gay, young and White. They were less likely to be Black, or injection drug users. The proposed study has the potential to have a significant impact upon screening for HIV, syphilis, and HCV. Rapid tests have the potential to increase the receipt of test results, particularly among groups that are less likely to return for their results using traditional testing. The candidate tests are designed for Point of Care (either oral fluid and/or whole blood), and thus will require real-time testing, so the trial will be able to evaluate both the accuracy of the tests in settings of intended use and their acceptability to potential clients in real-world situations.

02

Conditions studied

  • HIV
  • Hepatitis C
  • Hepatitis B
  • Syphilis

Keywords

  • diagnosis screening
  • HIV serodiagnosis
  • HCV antibodies
  • serologic tests
  • Bedside testing
  • diagnostic test kits
  • syphilis serodiagnosis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Over 17 years old
  • Mentally stable
  • Sober
  • Able to understand English or Spanish
  • At least one good vein for phlebotomy
  • Member of Behavioral Risk Group
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
1,200 participants (actual)

Study arms

  • Experimental
    All tests.

    Choose from all 16 possible tests.

    Device: Rapid tests for HIV, HCV, HBV, and syphilis

  • Active comparator
    HIV/HCV

    Choice of 10 different HIV and hepatitis C tests in the bundle.

    Device: HIV/HCV

  • Active comparator
    HIV/Syphilis

    Choice of 7 different tests for HIV and syphilis.

    Device: HIV/syphilis

  • Active comparator
    HIV only

    Choice of 4 rapid tests for HIV only.

    Device: HIV only

Interventions

  • DeviceRapid tests for HIV, HCV, HBV, and syphilis

    Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.

    Also known as: INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.), Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.), DPP® HIV 1/2 Screen Assay (Chembio, Inc.), OraQuick HCV antibody test (Orasure), DPP® HCV Screen Assay (Chembio, Inc.), DPP® HIV-HCV Screen Assay (Chembio, Inc.), Multiplo Rapid HIV/HCV Antibody Test (MedMira, Inc.), DPP® Syphilis Screen & Confirm Assay (Chembio, Inc.), DPP® HIV-Syphilis Screen Assay (Chembio, Inc.), DPP® HIV-HCV-Syphilis Screen Assay (Chembio, Inc.), Multiplo Rapid HIV/HCV/HBV Antibody Test (MedMira, Inc.)

  • DeviceHIV/HCV

    Choice of 10 different tests for HIV and hepatitis C.

    Also known as: INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.), Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.), DPP® HIV 1/2 Screen Assay (Chembio, Inc.), OraQuick HCV antibody test (Orasure), DPP® HCV Screen Assay (Chembio, Inc.), DPP® HIV-HCV Screen Assay (Chembio, Inc.), Multiplo Rapid HIV/HCV Antibody Test (MedMira, Inc.)

  • DeviceHIV/syphilis

    Choice of 7 different tests for HIV and syphilis

    Also known as: INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.), Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.), DPP® HIV 1/2 Screen Assay (Chembio, Inc.), DPP® Syphilis Screen & Confirm Assay (Chembio, Inc.), DPP® HIV-Syphilis Screen Assay (Chembio, Inc.)

  • DeviceHIV only

    Choice of 4 different tests for HIV only.

    Also known as: INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.), Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.), DPP® HIV 1/2 Screen Assay (Chembio, Inc.)

05

What researchers measure

Primary outcomes

  1. Test choice profile

    Which tests do participants choose to receive when bundled in different combinations?

    Time frame: one day (day one of study)

Secondary outcomes

  1. Return for standard test results

    Is there a different return for test results rate for the different arms of the study?

    Time frame: one week

06

Study locations

1 site
  • Center for Behavioral Research and Services
    Long Beach, California 90813, United States
07

Registry details

Key details

Study ID
NCT01317784
Lead sponsor
California State University, Long Beach
Collaborators
National Institute on Drug Abuse (NIDA)
Responsible party
Dennis G. Fisher (Professor and Director, California State University, Long Beach) — Principal investigator
First posted
Mar 17, 2011
Start date
May 2011
Primary completion
Jun 2014
Completion
Aug 2014
Last update
Jul 29, 2015

Study contacts

Dennis G Fisher, Ph.D.
principal investigator · California State University, Long Beach

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion